249 related articles for article (PubMed ID: 26816834)
1. Active surveillance and focal therapy for low-intermediate risk prostate cancer.
Klotz L
Transl Androl Urol; 2015 Jun; 4(3):342-54. PubMed ID: 26816834
[TBL] [Abstract][Full Text] [Related]
2. Active surveillance for low-risk prostate cancer.
Klotz L
Curr Urol Rep; 2015 Apr; 16(4):24. PubMed ID: 25764118
[TBL] [Abstract][Full Text] [Related]
3. Defining 'progression' and triggers for curative intervention during active surveillance.
Klotz L
Curr Opin Urol; 2015 May; 25(3):258-66. PubMed ID: 25714238
[TBL] [Abstract][Full Text] [Related]
4. Active surveillance for low-risk prostate cancer.
Klotz L
Curr Opin Urol; 2017 May; 27(3):225-230. PubMed ID: 28267056
[TBL] [Abstract][Full Text] [Related]
5. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of Cancer Progression on Serial Biopsy in Men on Active Surveillance for Early-stage Prostate Cancer: Implications for Focal Therapy.
Fasulo V; Cowan JE; Maggi M; Washington SL; Nguyen HG; Shinohara K; Lazzeri M; Casale P; Carroll PR
Eur Urol Oncol; 2022 Feb; 5(1):61-69. PubMed ID: 33069628
[TBL] [Abstract][Full Text] [Related]
7. Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.
van der Poel H; Klotz L; Andriole G; Azzouzi AR; Bjartell A; Cussenot O; Hamdy F; Graefen M; Palma P; Rivera AR; Stief CG
World J Urol; 2015 Jul; 33(7):907-16. PubMed ID: 26037891
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
Willemse PM; Davis NF; Grivas N; Zattoni F; Lardas M; Briers E; Cumberbatch MG; De Santis M; Dell'Oglio P; Donaldson JF; Fossati N; Gandaglia G; Gillessen S; Grummet JP; Henry AM; Liew M; MacLennan S; Mason MD; Moris L; Plass K; O'Hanlon S; Omar MI; Oprea-Lager DE; Pang KH; Paterson CC; Ploussard G; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; Van den Broeck T; van der Kwast TH; van der Poel HG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TBL
Eur Urol; 2022 Apr; 81(4):337-346. PubMed ID: 34980492
[TBL] [Abstract][Full Text] [Related]
9. Active Surveillance for Prostate Cancer: How to Do It Right.
Garisto JD; Klotz L
Oncology (Williston Park); 2017 May; 31(5):333-40, 345. PubMed ID: 28512731
[TBL] [Abstract][Full Text] [Related]
10. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
11. Targeted Prostate Biopsy and MR-Guided Therapy for Prostate Cancer.
Woodrum DA; Kawashima A; Gorny KR; Mynderse LA
Adv Exp Med Biol; 2018; 1096():159-184. PubMed ID: 30324353
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.
Klotz L
Nat Clin Pract Urol; 2005 Mar; 2(3):136-42; quiz 1 p following 149. PubMed ID: 16474710
[TBL] [Abstract][Full Text] [Related]
13. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
14. Active surveillance in intermediate-risk prostate cancer.
Klotz L
BJU Int; 2020 Mar; 125(3):346-354. PubMed ID: 31647166
[TBL] [Abstract][Full Text] [Related]
15. Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies.
Gallagher KM; Christopher E; Cameron AJ; Little S; Innes A; Davis G; Keanie J; Bollina P; McNeill A
BJU Int; 2019 Mar; 123(3):429-438. PubMed ID: 30113755
[TBL] [Abstract][Full Text] [Related]
16. Active surveillance versus radical treatment for favorable-risk localized prostate cancer.
Klotz L
Curr Treat Options Oncol; 2006 Sep; 7(5):355-62. PubMed ID: 16904052
[TBL] [Abstract][Full Text] [Related]
17. Low-risk Prostate Cancer: Identification, Management, and Outcomes.
Moschini M; Carroll PR; Eggener SE; Epstein JI; Graefen M; Montironi R; Parker C
Eur Urol; 2017 Aug; 72(2):238-249. PubMed ID: 28318726
[TBL] [Abstract][Full Text] [Related]
18. Management of low risk prostate cancer: active surveillance and focal therapy.
Klotz L; Emberton M
Curr Opin Urol; 2014 May; 24(3):270-9. PubMed ID: 24710055
[TBL] [Abstract][Full Text] [Related]
19. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer.
Klotz L
J Urol; 2004 Nov; 172(5 Pt 2):S48-50; discussion S50-1. PubMed ID: 15535443
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
